Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing unprecedented clinical benefits. However, primary or acquired therapy resistance can affect up to two-thirds of patients receiving ICIs, underscoring the urgency to elucidate the mechanisms of treatment resi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Yan, Yiyi, Kumar, Anagha Bangalore, Finnes, Heidi, Markovic, Svetomir N., Park, Sean, Dronca, Roxana S., Dong, Haidong
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6072836/
https://ncbi.nlm.nih.gov/pubmed/30100909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01739
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados